References
- 1. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-59.
- 2. Mattick JS. The Genetic Signatures of Noncoding RNAs. PLoS Genet 2009; 5.
- 3. Eddy SR. Non-coding RNA genes and the modern RNA world. Nat RevGenet 2001; 2: 919-29.
- 4. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-9.
- 5. Kapranov P, Drenkow J, Cheng J, Long J, Helt G, Dike S, et al. Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays. Genome Res 2005; 15: 987-97.
- 6. Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med 2012; 10: 103.
- 7. Zen K, Zhang CY. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32: 326-48.
- 8. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol 2010; 220: 126-39.
- 9. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat RevClin Oncol 2011; 8: 467-77.
- 10. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu RevBiochem 2012; 81: 145-66.
- 11. Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Bio 2011; 12: 246-58.
- 12. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer 2012; 12: 84-8.
- 13. Montanaro L, Trere D, Derenzini M. Nucleolus, ribosomes, and cancer. AmJ Pathol 2008; 173: 301-10.
- 14. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010; 28: 570-9.
- 15. Mesojednik S, Kamensek U, Cemazar M. Evaluation of shRNA-mediated gene silencing by electroporation in LPB fibrosarcoma cells. Radiol Oncol 2008; 42: 82-92.
- 16. Wu XY, Zhong DX, Lin B, Zhai WL, Ding ZQ, Wu J. p38 MAPK regulates the expression of ether a go-go potassium channel in human osteosarcoma cells. Radiol Oncol 2013; 47: 42-9.
- 17. Zhao SH, Zhao F, Zheng JY, Gao LF, Zhao XJ, Cui MH. Knockdown of stat3 expression by RNAi inhibits in vitro growth of human ovarian cancer. RadiolOncol 2011; 45: 196-203.
- 18. Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011; 11: 500.
- 19. Bustin SA, Murphy J. RNA biomarkers in colorectal cancer. Methods 2013; 59: 116-25.
- 20. Bresters D, Schipper MEI, Reesink HW, Boesernunnink BDM, Cuypers HTM. The Duration of Fixation Influences the Yield of Hcv Cdna-Pcr Products from Formalin-Fixed, Paraffin-Embedded Liver-Tissue. J Virol Methods 1994; 48: 267-72.
- 21. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004; 164: 35-42.
- 22. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nature Methods 2004; 1: 155-61.
- 23. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009; 89: 597-606.
- 24. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27: 4373-9.
- 25. Asangani IA, Rasheed SAK, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
- 26. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered microRNA expression confined to specific epithelial cell Subpopulations in breast cancer. Cancer Res 2007; 67: 11612-20.
- 27. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
- 28. Wang FJ, Zheng ZG, Guo JF, Ding XF. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010; 119: 586-93.
- 29. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 Differentiates Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and Early Stage Disease. Oncologist 2010; 15: 673-82.
- 30. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, et al. Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non-Small-Cell Lung Carcinoma. J ClinOncol 2009; 27: 2030-7.
- 31. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011; 5: 281-91.
- 32. Xiao BX, Guo JM, Miao Y, Jiang Z, Huan R, Zhang YY, et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta 2009; 400: 97-102.
- 33. Zhang YY, Guo JM, Li D, Xiao BX, Miao Y, Jiang Z, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. MedOncol 2010; 27: 685-9.
- 34. Zhang CN, Wang C, Chen X, Yang CH, Li K, Wang JJ, et al. Expression Profile of MicroRNAs in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma. Clin Chem 2010; 56: 1871-9.
- 35. Liu R, Zhang CN, Hu ZB, Li G, Wang C, Yang CH, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-91.
- 36. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama-J Am Med Assoc 2007; 297: 1901-8.
- 37. Habbe N, Koorstra JBM, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. CancerBiol Ther 2009; 8: 340-6.
- 38. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, et al. MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions. Clin Chem 2010; 56: 603-12.
- 39. Kong XY, Du YQ, Wang GK, Gao J, Gong YF, Li L, et al. Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. Dig Dis Sci 2011; 56: 602-9.
- 40. Ho AS, Huang X, Cao HB, Christman-Skieller C, Bennewith K, Le QT, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. TranslOncol 2010; 3: 109-13.
- 41. Wang J, Chen JY, Chang P, LeBlanc A, Li DH, Abbruzzesse JL, et al. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease. Cancer Prev Res 2009; 2: 807-13.
- 42. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-8.
- 43. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-7.
- 44. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res 2011; 17: 5287-98.
- 45. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127: 2768-76.
- 46. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
- 47. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
- 48. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128: 608-16.
- 49. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: Elevated Levels in Patients With Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy. Prostate 2011; 71: 326-31.
- 50. Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biology 2011; 32: 583-8.
- 51. Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. BrJ Cancer 2012; 106: 768-74.
- 52. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243-9.
- 53. Huang ZH, Huang D, Ni SJA, Peng ZL, Sheng WQ, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. IntJ Cancer 2010; 127: 118-26.
- 54. Cheng HY, Zhang LN, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis. PLoS One 2011; 6: e17745.
- 55. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011; 225: 43-53.
- 56. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6.
- 57. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large Intervening Non-coding RNA HOTAIR is Associated with Hepatocellular Carcinoma Progression. J Int MedRes 2011; 39: 2119 - 28.
- 58. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008; 451: 202-6.
- 59. Chen W, Böcker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human tumours. J Pathol 1997; 183: 345-51.
- 60. Iacoangeli A, Lin Y, Morley EJ, Muslimov IA, Bianchi R, Reilly J, et al. BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis 2004; 25: 2125-33.
- 61. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102: 245-52.
- 62. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted noncoding RNA in growth and development. Bioessays 2010; 32: 473-80.
- 63. Hibi K, Nakamura H, Hirai A, al. e. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996; 56: 480-2.
- 64. Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T, et al. H19 expression in hepatic metastases from a range of human carcinomas. J ClinPathol 2005; 58: 1064-8.
- 65. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007; 2: e845.
- 66. Arima T, Matsuda T, Takagi N, Wake N. Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genet Cytogenet 1997; 93: 39-47.
- 67. Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 2005; 280: 29625-36.
- 68. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allelespecific binding to potentiate tumorigenesis. Cancer Res 2006; 66: 5330-7.
- 69. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-93.
- 70. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18: 1243-50.
- 71. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol 2009; 21: 688-92.
- 72. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132: 330-42.
- 73. Guffanti A, Iacono M, Pelucchi P, Kim N, Solda G, Croft LJ, et al. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics 2009; 10: 163.
- 74. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, et al. Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci 2006; 97: 106-12.
- 75. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26: 851-8.
- 76. Luo JH, Ren B, Keryanov S, Tsang GC, Reo UNM, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-24.
- 77. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2008; 93: 4119-25.
- 78. Benetatos L, Vartholomatos G, Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 2011; 129: 773-9.
- 79. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-8.
- 80. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 2011; 71: 3852-62.
- 81. Lanz RB, Chua SS, Barron N, Soder BM, DeMayo F, O’Malley BW. Steroid Receptor RNA Activator Stimulates Proliferation as Well as Apoptosis In Vivo. Mol Cell Biol 2003; 23: 7163-76.
- 82. Chooniedass-Kothari S, Vincett D, Yan Y, Cooper C, Hamedani MK, Myal Y, et al. The protein encoded by the functional steroid receptor RNA activator is a new modulator of ER alpha transcriptional activity. FEBS Lett 2010; 584: 1174-80.
- 83. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA upregulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 2008; 582: 1919-27.
- 84. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006; 12: 4851-8.
- 85. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-89.
- 86. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195-208.
- 87. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. MolCell 2010; 38: 662-74.
- 88. Rajaram V, Knezevich S, Bove KE, Perry A, Pfeifer JD. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosom Cancer 2007; 46: 508-13.
- 89. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012; 29: 1810-6.
- 90. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 2010; 3: ra8.
- 91. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.
- 92. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA Analysis in Urine - a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-7.
- 93. Neves AF, Dias-Oliveira JDD, Araujo TG, Marangoni K, Goulart LR. Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis. Clin Chem Lab Med 2013; 51: 881-7.
- 94. Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, et al. miRNA Expression in Colon Polyps Provides Evidence for a Multihit Model of Colon Cancer. PLoS One 2011; 6: e20465.
- 95. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-96.
- 96. Kota SK, Balasubramanian S. Cancer therapy via modulation of micro RNA levels: a promising future. Drug Discov Today 2010; 15: 733-40.
- 97. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-6.
- 98. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011; 18: 1104-10.
- 99. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
- 100. Bader AG, Brown D, Winkler M. The Promise of MicroRNA Replacement Therapy. Cancer Res 2010; 70: 7027-30.
- 101. Dolinsek T, Markelc B, Sersa G, Coer A, Stimac M, Lavrencak J, et al. Multiple Delivery of siRNA against Endoglin into Murine Mammary Adenocarcinoma Prevents Angiogenesis and Delays Tumor Growth. PLoSOne 2013; 8: e58723.
- 102. Todorovic V, Sersa G, Cemazar M. Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28. Cancer Gene Ther 2013; 20: 208-10.
- 103. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
- 104. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature Methods 2007; 4: 721-6.
- 105. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-52.
- 106. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29: 1580-7.
- 107. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 micro- RNA family. Proc Natl Acad Sci USA 2008; 105: 3903-8.
- 108. Ji Q, Hao X, Meng Y, Zhang M, DeSano J, Fan DM, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
- 109. Gutschner T, Baas M, Diederichs S. Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res 2011; 21: 1944-54.
- 110. Borralho PM, Simoes AES, Gomes SE, Lima RT, Carvalho T, Ferreira DMS, et al. miR-143 Overexpression Impairs Growth of Human Colon Carcinoma Xenografts in Mice with Induction of Apoptosis and Inhibition of Proliferation. PLoS One 2011; 6: e23787.
- 111. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 2009; 7: 69.